Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Viracta Therapeutics News

    0,84 $ +0,44% +0,0037 $
    In : 0,7829 € | 21:54:06 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2QQRS
    ISIN: US92765F1084
    US-Symbol: VIRX
    Typ: Aktie

    Viracta Therapeutics News

    08.03.24 - PR Newswire
    Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
    Thinking about buying stock in Quantum-​Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser? PR Newswire
    19.09.22 - PR Newswire
    Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth
    Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth PR Newswire
    07.09.22 - PR Newswire
    Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma
    Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma PR Newswire
    16.08.22 - PR Newswire
    Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases
    Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-​Barr Virus and Associated ...
    11.08.22 - PR Newswire
    Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
    Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors PR Newswire
    09.08.22 - PR Newswire
    Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
    Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates PR Newswire
    13.06.22 - PR Newswire
    Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award
    Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award PR Newswire
    02.06.22 - PR Newswire
    Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting
    Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-​Barr Virus-​Positive (EBV+) Solid Tumors and Announces Upcoming ...
    01.06.22 - PR Newswire
    Viracta Therapeutics to Present at the Jefferies Healthcare Conference
    Viracta Therapeutics to Present at the Jefferies Healthcare Conference PR Newswire
    13.05.22 - PR Newswire
    Viracta Therapeutics Announces New Employment Inducement Grant
    Viracta Therapeutics Announces New Employment Inducement Grant PR Newswire
    11.05.22 - PR Newswire
    Viracta Therapeutics to Present at Upcoming May Investor Conferences
    Viracta Therapeutics to Present at Upcoming May Investor Conferences PR Newswire
    10.05.22 - PR Newswire
    Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
    Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates PR Newswire
    20.04.22 - PR Newswire
    Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors
    Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-​Barr Virus-​Positive Solid Tumors PR Newswire
    09.03.22 - PR Newswire
    Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
    Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference PR Newswire
    10.02.22 - PR Newswire
    Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
    Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire
    31.01.22 - PR Newswire
    Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
    Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-​Barr Virus-​Positive Solid Tumors First clinical trial to evaluate ...
    04.01.22 - PR Newswire
    Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
    Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire
    16.12.21 - PR Newswire
    Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index
    Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index PR Newswire
    13.12.21 - PR Newswire
    Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021
    Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021 Vecabrutinib enhanced the efficacy of CAR T-cells in a murine mantle cell ...
    13.12.21 - PR Newswire
    Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
    Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-​Barr Virus-​Positive ...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »